title: In vitro cellular cytotoxicity in Crohn's disease and ulcerative colitis: relation with disease activity and treatment, and the effect of recombinant gamma-interferon.
abstract: In a previous study using total mononuclear cells and lymphocytes, enriched by elutriation centrifugation, of patients with Crohn's disease and ulcerative colitis were found to have a decreased NK cell activity. In the present study the relation with disease activity and treatment, and the effect of recombinant gamma-interferon (gamma-IFN) on NK cell and monocyte cytotoxicity has been studied in 19 patients with Crohn's disease, 11 with ulcerative colitis, two with indeterminate colitis and 12 healthy controls. Patients with active Crohn's disease and active ulcerative colitis were shown to have an impaired NK cell activity compared to the control group. However, no difference was found in the percentage of CD16 (Leu 11+) cells, as determined by fluorocytometry, between patients with active or inactive disease. Moreover, the NK cell impairment was not related to corticosteroid treatment. Recombinant gamma-interferon (gamma-IFN) stimulated significantly the cytotoxic activity of the total mononuclear cells and the monocyte-enriched fraction against all target cell lines, both in patients and controls. No relation was found between the increase in cytotoxicity by gamma-IFN and disease activity in the patients. Stimulation with gamma-IFN demonstrated that the monocyte cytotoxic response of inflammatory bowel disease patients is normal. The present study reveals that the impairment in NK cell activity in patients with inflammatory bowel disease is related to disease activity and therefore suggests to be secondary to the inflammatory process.
authors.affiliation: Department of Gastroenterology and Hepatology, University Hospital, Leiden, The Netherlands.
authors.forename: M N
authors.initials: MN
authors.lastname: Aparició-Pagés
authors.forename: H W
authors.initials: HW
authors.lastname: Verspaget
authors.forename: A S
authors.initials: AS
authors.lastname: Peña
authors.forename: I T
authors.initials: IT
authors.lastname: Weterman
authors.forename: P A
authors.initials: PA
authors.lastname: de Bruin
authors.forename: M A
authors.initials: MA
authors.lastname: Mieremet-Ooms
authors.forename: J M
authors.initials: JM
authors.lastname: van der Zon
authors.forename: E A
authors.initials: EA
authors.lastname: van Tol
authors.forename: C B
authors.initials: CB
authors.lastname: Lamers
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000276:immunology*; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D011994:Recombinant Proteins
chemical_list: D000305:Adrenal Cortex Hormones; D011994:Recombinant Proteins; D007371:Interferon-gamma